The FDA just approved Tecentriq for early-stage colon cancer after surgery, making it the first checkpoint inhibitor to land an adjuvant colorectal label. Genentech's ATOMIC trial cut recurrence risk in half for a specific group of patients, and the competitive implications are significant.
A Nine-Year Journey From Last Resort to First Option
For nearly a decade, immunotherapy drugs have been the cavalry for colon cancer patients who were already losing the war. Tumors had spread. Options were dwindling. Checkpoint inhibitors like pembrolizumab (Keytruda) showed up late in the game, rescuing a specific slice of patients whose cancers carried a biological quirk called mismatch repair deficiency, or dMMR.
Now, for the first time, the FDA has approved one of these drugs for patients who aren't in crisis yet. On October 8, the agency greenlit Genentech's atezolizumab (Tecentriq) in combination with chemotherapy for stage III dMMR colon cancer patients after surgery. That's not metastatic. Not unresectable. It's the adjuvant setting: the "let's make sure this doesn't come back" phase of treatment.
This is a big deal, and it took nearly a decade to get here.
A Quick Decoder Ring
Before we go further, let's translate. Mismatch repair deficiency (dMMR) means a tumor's DNA repair system is broken. Think of it like a spellchecker that's been turned off: errors pile up fast, creating tons of mutations. Those mutations make the cancer cells look obviously foreign to the immune system, which is exactly why checkpoint inhibitors work so well against them. The drugs essentially remove the blindfold from immune cells, letting them see (and attack) the mutant invaders.
About 15% of colorectal cancers carry this dMMR trait. It's a meaningful minority, not a rare curiosity.
Why Chemo Alone Wasn't Cutting It
The previous standard of care for stage III dMMR colon cancer after surgery was FOLFOX (a fluoropyrimidine plus oxaliplatin). Solid chemotherapy backbone. Proven in broad colon cancer populations.
But there was a problem hiding in the data. Patients with dMMR tumors appeared to get less benefit from fluoropyrimidine-based chemo alone compared to patients with normal DNA repair systems. The spellchecker analogy works here too: dMMR tumors are biologically distinct creatures, and the chemo cocktail that works well for "normal" colon cancers isn't fully optimized for them.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Oncologists knew these patients needed something better. They just had to prove it.
The ATOMIC Trial: Halving the Risk
Enter the ATOMIC trial, a phase III, randomized, open-label study that tested a simple hypothesis: what happens if you add Tecentriq to the standard FOLFOX regimen after surgery for stage III dMMR colon cancer?
The answer was striking. At a median follow-up of about 41 months, 86.3% of patients on Tecentriq plus chemo were disease-free at three years, compared to 76.2% on chemo alone. That translates to a hazard ratio of 0.50, which in plain English means the combination cut the risk of cancer recurrence or death roughly in half.
In oncology, a 50% risk reduction in a phase III adjuvant trial is the kind of number that makes rooms full of scientists stand up.
There's a caveat worth noting, though. The trial reported high rates of serious (grade 3/4) side effects, and treatment-related deaths occurred in the experimental arm. Adding immunotherapy to chemo isn't free. It's a real trade-off, and it may slow how quickly some oncologists reach for this combination in practice.
From Metastatic Miracle to Surgical Safety Net
To appreciate why this approval matters, you need to see the arc of immunotherapy in dMMR colorectal cancer. It reads like a movie where the hero keeps getting promoted.
Act 1 (2017): The FDA gives pembrolizumab accelerated approval for any MSI-H/dMMR solid tumor that has spread or can't be removed. It was a landmark, the first tissue-agnostic cancer approval ever. In early data, 40% of dMMR colorectal cancer patients responded to PD-1 blockade, while exactly 0% of patients with normal repair systems did.
Act 2 (2020): Pembrolizumab gets approved as first-line treatment for metastatic dMMR colorectal cancer. Immunotherapy officially moves from last resort to first option, but only for advanced disease.
Act 3 (2022–2025): Investigators start testing checkpoint inhibitors before surgery (the neoadjuvant setting) and see jaw-dropping complete response rates in dMMR rectal cancer. The field starts buzzing: can we push these drugs even earlier?
Act 4 (October 2026): Tecentriq gets the adjuvant nod. Immunotherapy has now officially moved from the emergency room to the recovery room.
First Mover in an Empty Room
What makes this approval commercially interesting is the competitive vacuum. Prior to October 8, no checkpoint inhibitor had been approved for early-stage colorectal cancer, period. Opdivo (nivolumab), dostarlimab, pembrolizumab: all approved or studied in the metastatic space, none with an adjuvant CRC label.
Genentech and parent company Roche now own the only approved immunotherapy for post-surgical colon cancer. That's a meaningful head start. The patient population is relatively niche (biomarker-defined, stage III only), so this isn't going to be a Keytruda-in-lung-cancer-sized revenue event. But it's incremental growth for the Tecentriq franchise at a time when the drug faces biosimilar pressure in some of its older indications.
The FDA also approved Tecentriq Hybreza, the subcutaneous formulation, for the same indication in patients 12 and older weighing at least 40 kg. That's a convenience play; infusion chairs are expensive, and a shot is faster than an IV drip.
The Bigger Picture
This approval sits at the intersection of two powerful trends in oncology. The first is biomarker-driven treatment selection: the idea that a tumor's molecular ID card matters more than where it started growing. The second is the relentless push to use effective drugs earlier, when cure is still on the table, rather than waiting until the disease is advanced and outcomes are grim.
For the roughly 15% of colon cancer patients whose tumors carry the dMMR flag, this changes the post-surgery conversation. FOLFOX alone is no longer the default. NCCN guidelines (v1.2026) already list FOLFOX plus atezolizumab as a preferred adjuvant regimen for this group.
Other pharma companies are running their own perioperative dMMR trials, testing PD-1 combinations and dual-checkpoint strategies. The race to own early-stage dMMR colorectal cancer is just beginning. But for now, Genentech crossed the finish line first.
And after nine years of immunotherapy proving itself in colon cancer one stage at a time, that finish line just moved a lot closer to the operating table.
4 min read
Roche Is Hiring a Chinese Startup to Invent Its Next Cancer Drug
Roche signed a deal worth up to $1 billion with Defand Therapeutics, a two-year-old Chinese startup with zero clinical trials, to discover molecular glue cancer drugs. It's Roche's fourth China partnership since August, and it signals a radical shift in how big pharma thinks about drug discovery.
